Tenaya Therapeutics Inc Total Assets
Tenaya Therapeutics Inc total assets. Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) holds total assets worth $104.98 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tenaya Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Tenaya Therapeutics Inc (2019–2024)
Total assets of Tenaya Therapeutics Inc from 2019 to 2024. This chart illustrates how Tenaya Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Tenaya Therapeutics Inc (TNYA) share price today for real-time trading data and today's change.
Tenaya Therapeutics Inc - Asset Composition Analysis
Tenaya Therapeutics Inc Total Assets Breakdown (December 2024)
Tenaya Therapeutics Inc total assets breakdown as of December 2024. Tenaya Therapeutics Inc's total assets of $104.98 Million consist of 56.2% current assets and 43.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Tenaya Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tenaya Therapeutics Inc's current assets represent 56.2% of total assets in 2024, a decrease from 73.0% in 2019.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2024, down from 62.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Tenaya Therapeutics Inc Competitors by Total Assets
Key competitors of Tenaya Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Tenaya Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.64 | 5.27 | 25.78 |
| Quick Ratio | 4.64 | 5.27 | 25.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $48.03 Million | $69.15 Million | $124.92 Million |
Tenaya Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Tenaya Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.72 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | -29.7% |
| Total Assets | $119.94 Million |
| Market Capitalization | $78.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Tenaya Therapeutics Inc's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tenaya Therapeutics Inc's assets decreased by 29.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Tenaya Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $119.94 Million | -29.66% |
| 2023-12-31 | $170.51 Million | -38.87% |
| 2022-12-31 | $278.94 Million | -11.91% |
| 2021-12-31 | $316.65 Million | +113.72% |
| 2020-12-31 | $148.16 Million | +289.89% |
| 2019-12-31 | $38.00 Million | -- |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more